Showing 4611-4620 of 8849 results for "".
- Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impacthttps://practicaldermatology.com/news/post-market-price-changes-alone-account-for-most-recent-spending-growth-for-biologics-and-rebates-have-little-impact/2460214/Annual spending on biologics by U.S. public programs and beneficiaries nearly doubled from 2012 to 2016, according to research presented
- Dr. Roy Geronemus Awarded the Inaugural Vic Narurkar, MD Innovations in Aesthetic Dermatology Lectureship Awardhttps://practicaldermatology.com/news/dr-roy-geronemus-awarded-the-vic-narurkar-md-innovations-in-aesthetic-dermatology-lectureship-award/2460210/Roy Geronemus, MD of Laser & Skin Surgery Center of New York received, The American Society for Dermatologic Surgery inaugural Vic Narurkar, M.D., Innovations in Aesthetic Dermatology Lectureship Award Dr. Geronemus received the award at the 2019 ASDS annual meeting in Chicago. He d
- ASDSA Honors 2019 Patient Safety Heroeshttps://practicaldermatology.com/news/asdsa-honors-2019-patient-safety-heroes/2460203/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipients of its annual Patient Safety Hero awards at the recent ASDS Annual Meeting in Chicago, Illinois. The ASDSA State Legislative Patient Safety Hero Award is presented to a state legislative member who
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of
- EPI Health Acquires Worldwide Rights to Rhofade from Aclarishttps://practicaldermatology.com/news/epi-health-acquires-worldwide-rights-to-rhofade-from-aclaris/2460180/EPI Health, LLC, has acquired Rhofade (oxymetazoline hydrochloride) cream, 1% and related intellectual property assets from Aclaris Therapeutics, Inc. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. “We are excited ab
- Research Substantiates Psoriasis/Non-alcoholic Fatty Liver Disease Linkhttps://practicaldermatology.com/news/research-substantiates-psoriasisnon-alcoholic-fatty-liver-disease-link/2460174/The severity of psoriasis is related to the severity of non-alcoholic fatty liver disease (NAFLD), according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Patients with psoriasis and NAFLD had more severe hepatic damage if they had a higher s
- La Roche-Posay Foundation Opens Call for Abstractshttps://practicaldermatology.com/news/la-roche-posay-foundation-opens-call-for-abstracts/2460163/The La Roche-Posay North American Foundation has opened a call for scientific abstracts. The La Roche-Posay North American Foundation was established in 2005 to support outstanding candidates with promising projects in the field of clinical, biological or pharmacological research linked to
- With New Funding, Turn Therapeutics Will Launch Phase 4 Study of AD Drughttps://practicaldermatology.com/news/with-new-funding-turn-therapeutics-will-launch-phase-4-study-of-ad-drug/2460162/Turn Therapeutics has closed its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX Eczema Emulsion, with enrollment scheduled to begin in Q1 2020. The series B financing will also support advancement of additional i
- Electric Tech May Help Reverse Baldnesshttps://practicaldermatology.com/news/electric-tech-may-help-reverse-baldness/2460156/Reversing baldness could someday be as easy as wearing a hat, thanks to a noninvasive, low-cost hair-growth-stimulating technology developed by engineers at the University of Wisconsin–Madison. Xudong Wang, a professor of materials science and engineering at UW–Madison. and
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identifie